Evaluation of the therapeutic efficacy of a VEGFR2-blocking antibody using sodium-iodide symporter molecular imaging in a tumor xenograft model

Nuclear Medicine and Biology

Volumn 38, Issue 1, 2011, Pages 93-101

  Cheong, Su Jin ^a   Lee, Chang Moon ^a   Kim, Eun Mi ^a   Uhm, Tai Boong ^b   Jeong, Hwan Jeong ^a   Kim, Dong Wook ^a   Lim, Seok Tae ^a   Sohn, Myung Hee ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Chonbuk National University   (South Korea)

Author keywords

DC101; Gene transfection; Human sodium iodide symporter; Molecular imaging; Reporter gene

Indexed keywords

CD31 ANTIGEN; IODINE 125; LIPOFECTAMINE; MONOCLONAL ANTIBODY DC101; RECEPTOR ANTIBODY; SODIUM IODIDE SYMPORTER; TECHNETIUM 99M; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2 ANTIBODY;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TUMOR LEVEL; DRUG UPTAKE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR IMAGING; NONHUMAN; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR IMAGING; NEOVASCULARIZATION, PATHOLOGIC; RATS; SYMPORTERS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650968654     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.05.009     Document Type: Article

References (36)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31.
2. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
3. Shinkaruk S., Bayle M., Laïn G., Déléris G. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents 2003, 3:95-117.
4. Plate K.H., Breier G., Millauer B., Ullrich A., Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 1993, 53:5822-5827.
5. Klagsbrun M., D'Amore P.A. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996, 7:259-270.
6. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993, 362:841-844.
7. Brekken R.A., Overholser J.P., Stastny V.A., Waltenberger J., Minna J.D., Thorpe P.E. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000, 60:5117-5124.
8. Strawn L.M., McMahon G., App H., Schreck R., Kuchler W.R., Longhi M.P., et al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996, 56:3540-3545.
9. Witte L., Hicklin D.J., Zhu Z., Pytowski B., Kotanides H., Rockwell P., et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 1998, 17:155-161.
10. Prewett M., Huber J., Li Y., Santiago A., O'Connor W., King K., et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999, 59:5209-5218.
11. Blasberg R.G., Gelovani-Tjuvajev J. In vivo molecular-genetic imaging. J Cell Biochem Suppl 2002, 39:172-183.
12. Kang J.H., Chung J.K. Molecular-genetic imaging based on reporter gene expression. J Nucl Med 2008, 49:164-179.
13. Serganova I., Mayer-Kukuck P., Huang R., Blasberg R. Molecular imaging: reporter gene imaging. Handb Exp Pharmacol 2008, 185:167-223.
14. Herschman H.R. Noninvasive imaging of reporter gene expression in living subjects. Adv Cancer Res 2004, 92:29-80.
15. Filetti S., Bidart J.M., Arturi F., Caillou B., Russo D., Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 1999, 141:443-457.
16. Hsieh Y.J., Ke C.C., Liu R.S., Wang F.H., Tang K.T., Chi C.W., et al. Radioiodide imaging and treatment of ARO cancer xenograft in a mouse model after expression of human sodium iodide symporter. Anticancer Res 2007, 27:2515-2522.
17. Cengic N., Baker C.H., Schütz M., Göke B., Morris J.C., Spitzweg C. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab 2005, 90:4457-4464.
18. Smit J.W., Schröder-van der Elst J.P., Karperien M., Que I., Stokkel M., van der Heide D., et al. Iodide kinetics and experimental 131I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line. J Clin Endocrinol Metab 2002, 87:1247-1253.
19. Heufelder A.E., Morgenthaler N., Schipper M.L., Joba W. Sodium iodide symporter-based strategies for diagnosis and treatment of thyroidal and nonthyroidal malignancies. Thyroid 2001, 11:839-847.
20. Chung J.K. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 2002, 43:1188-2000.
21. Rao V.P., Miyagi N., Ricci D., Carlson S.K., Morris J.C., Federspiel M.J., et al. Sodium iodide symporter (hNIS) permits molecular imaging of gene transduction in cardiac transplantation. Transplantation 2007, 84:1662-1666.
22. Niu G., Krager K.J., Graham M.M., Hichwa R.D., Domann F.E. Noninvasive radiological imaging of pulmonary gene transfer and expression using the human sodium iodide symporter. Eur J Nucl Med Mol Imaging 2005, 32:534-540.
23. Groot-Wassink T., Aboagye E.O., Wang Y., Lemoine N.R., Reader A.J., Vassaux G. Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther 2004, 9:436-442.
24. Niu G., Gaut A.W., Ponto L.L., Hichwa R.D., Madsen M.T., Graham M.M., et al. Multimodality noninvasive imaging of gene transfer using the human sodium iodide symporter. J Nucl Med 2004, 45:445-449.
25. Dwyer R.M., Bergert E.R., O'connor M.K., Gendler S.J. Morris JC. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res 2005, 11:1483-1489.
26. Dwyer R.M., Bergert E.R., O'Connor M.K., Gendler S.J., Morris J.C. Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice. Gene Ther 2006, 13:60-66.
27. Shin J.H., Chung J.K., Kang J.H., Lee Y.J., Kim K.I., So Y., et al. Noninvasive imaging for monitoring of viable cancer cells using a dual-imaging reporter gene. J Nucl Med 2004, 45:2109-2115.
28. Franco M., Man S., Chen L., Emmenegger U., Shaked Y., Cheung A.M., et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 2006, 66:3639-3648.
29. Cho J.Y., Shen D.H., Yang W., Williams B., Buckwalter T.L., La Perle K.M., et al. In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas. Gene Ther 2002, 9:1139-1145.
30. Park S.Y., Kwak W., Thapa N., Jung M.Y., Nam J.O., So I.S., et al. Combination therapy and noninvasive imaging with a dual therapeutic vector expressing MDR1 short hairpin RNA and a sodium iodide symporter. J Nucl Med 2008, 49:1480-1488.
31. Kiessling F., Farhan N., Lichy M.P., Vosseler S., Heilmann M., Krix M., et al. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. Neoplasia 2004, 6:213-223.
32. Fenton B.M., Paoni S.F., Ding I. Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors. Radiother Oncol 2004, 72:221-230.
33. Medarova Z., Rashkovetsky L., Pantazopoulos P., Moore A. Multiparametric Monitoring of Tumor Response to Chemotherapy by Noninvasive Imaging. Cancer Res 2009, 69:1182-1189.
34. Chen R.F., Li Z.H., Pan Q.H., Zhou J.J., Tang Q.B., Yu F.Y., et al. In vivo radioiodide imaging and treatment of pancreatic cancer xenografts after MUC1 promoter-driven expression of the human sodium-iodide symporter. Pancreatology 2007, 7:505-513.
35. Kim K.I., Kang J.H., Chung J.K., Lee Y.J., Jeong J.M., Lee D.S., et al. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells. J Nucl Med 2007, 48:1553-1561.
36. Jugold M., Palmowski M., Huppert J., Woenne E.C., Mueller M.M., Semmler W., et al. Volumetric high-frequency Doppler ultrasound enables the assessment of early antiangiogenic therapy effects on tumor xenografts in nude mice. Eur Radiol 2008, 18:753-758.